Disc Medicine, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Disc Medicine, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($212.18M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($109.36M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($76.43M) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | ($46.83M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($35.97M) | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | ($812.5K) | Mar 29, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($236.02M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($129.72M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | ($91.13M) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | ($47.48M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($30.93M) | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | ($817.0K) | Mar 29, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $806.88M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $496.77M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $368.00M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $200.21M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $92.41M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $8.32M | Mar 10, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $67.05M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $53.19M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $22.88M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $23.61M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $14.76M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $30.18M | Mar 10, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $739.83M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $443.59M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $345.12M | Feb 26, 2026 |
| FY2025 | Dec 31, 2022 | $176.60M | Feb 26, 2026 |
| FY2023 | Dec 31, 2021 | ($64.20M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | ($28.81M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | ($10.43M) | Mar 10, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | (45) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (40) | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | (3) | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | (3) | Feb 26, 2026 |
| FY2023 | Dec 31, 2022 | (45) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (40) | Mar 31, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $91.15M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $192.43M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $360.38M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $194.61M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $88.04M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $4.50M | Mar 10, 2022 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.16M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $28.32M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $0 | Feb 27, 2025 |
| FY2021 | Dec 31, 2020 | $14.00M | Mar 10, 2022 |